Skip to main content

ATORVASTATIN SANDOZ (Sandoz Pty Ltd)

Product name
ATORVASTATIN SANDOZ
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
132 working days (225)
Active ingredients
atorvastatin calcium trihydrate
Registration type
New generic medicine
Indication

ATORVASTATIN SANDOZ (film coated tablet) is indicated as an adjunct to diet for the treatment of patients with hypercholesterolaemia.

Prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemia, obstructive liver disease, other drug therapy, and alcoholism) should be identified and treated.

ATORVASTATIN SANDOZ is indicated in hypertensive patients with multiple risk factors for coronary heart disease (CHD) which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic CHD to reduce the risk of non-fatal myocardial infarction (MI) and non-fatal stroke.

These effects do not replace the need to independently control known causes of cardiovascular (CV) mortality and morbidity such as hypertension, diabetes and smoking.

Help us improve the Therapeutic Goods Administration site